These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 24638182)
1. In intracranial artery stenosis, adding angioplasty and stenting to medical therapy increased stroke or death. Hankey GJ Ann Intern Med; 2014 Mar; 160(6):JC4. PubMed ID: 24638182 [No Abstract] [Full Text] [Related]
2. Edoxaban versus warfarin for venous thromboembolism. Haft JI N Engl J Med; 2014 Jan; 370(1):80. PubMed ID: 24382070 [No Abstract] [Full Text] [Related]
3. Edoxaban versus warfarin for venous thromboembolism. Büller HR N Engl J Med; 2014 Jan; 370(1):80-1. PubMed ID: 24382069 [No Abstract] [Full Text] [Related]
4. ACP Journal Club. Edoxaban was noninferior to warfarin for preventing recurrent venous thromboembolism, with less bleeding. Thomé S Ann Intern Med; 2014 Jan; 160(2):JC4. PubMed ID: 24445714 [No Abstract] [Full Text] [Related]
5. Venous thromboembolism: Edoxaban: as effective and safer than warfarin in VTE. Lim GB Nat Rev Cardiol; 2013 Nov; 10(11):614. PubMed ID: 24042227 [No Abstract] [Full Text] [Related]
6. Which oral anticoagulant to use: factor Xa inhibitor or thrombin inhibitor? DAS S Natl Med J India; 2013; 26(4):221-2. PubMed ID: 24758448 [No Abstract] [Full Text] [Related]
7. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990 [TBL] [Abstract][Full Text] [Related]
8. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
10. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. ; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658 [TBL] [Abstract][Full Text] [Related]
11. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644 [TBL] [Abstract][Full Text] [Related]
12. Optimal duration of anticoagulation after venous thromboembolism. Goldhaber SZ; Piazza G Circulation; 2011 Feb; 123(6):664-7. PubMed ID: 21321182 [No Abstract] [Full Text] [Related]
13. Venous Thromboembolism Prophylaxis: Safe, but Still Provocative? Pelargos PE; Dunn IF Thromb Haemost; 2019 Nov; 119(11):1716-1718. PubMed ID: 31665802 [No Abstract] [Full Text] [Related]